The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Consolidated net loss | -74,123 |
| Depreciation and amortization | 664 |
| Stock-based compensation | 4,997 |
| Accretion of discount of available-for-sale investment securities | 1,854 |
| Amortization of right-of-use assets | 889 |
| Gain on disposal of property and equipment | 12 |
| Other receivables | -863 |
| Prepaid expenses and other assets | -7,334 |
| Accounts payable and accrued expenses | -33 |
| Operating lease liability | -711 |
| Net cash used in operating activities | -61,986 |
| Purchases of property and equipment | 77 |
| Purchases of available-for-sale investment securities | 93,445 |
| Maturities of available-for-sale investment securities | 88,457 |
| Proceeds from sale of property and equipment | 12 |
| Net cash (used in) provided by investing activities | -5,053 |
| Proceeds from issuance of common stock through option exercises | 19 |
| Proceeds from issuance of common stock through employee stock purchase plan | 108 |
| Proceeds from issuance of common stock from at-the-market offerings, net of offering costs | 66,423 |
| Proceeds from issuance of common stock from underwritten follow-on public offering, net of offering costs | 0 |
| Principal paid on finance lease liabilities | 539 |
| Net cash provided by financing activities | 66,011 |
| Net change in cash, cash equivalents and restricted cash | -1,028 |
| Cash, cash equivalents and restricted cash at beginning of period | 14,006 |
| Cash, cash equivalents and restricted cash at end of period | 12,978 |
aTYR PHARMA INC (ATYR)
aTYR PHARMA INC (ATYR)